# A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

> **NCT01142011** · PHASE2 · UNKNOWN · sponsor: **Cancer Trials Australia** · enrollment: 15 (estimated)

## Conditions studied

- Symptomatic Waldenstroms Macroglobulinaemia

## Interventions

- **DRUG:** Belimumab

## Key facts

- **NCT ID:** NCT01142011
- **Lead sponsor:** Cancer Trials Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-11
- **Primary completion:** 2012-06
- **Final completion:** 2013-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2012-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142011, "A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01142011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*